Related by context. All words. (Click for frequent words.) 60 mg BID dose 59 Tumor Response 59 HORIZONS AMI trial 58 CALGB 58 CIMZIA ™ 57 Acute Decompensated Heart Failure 57 clinico pathological 57 morphometric vertebral fractures 57 BCIRG 57 STRIDE PD 57 prospective multicentre 57 p# biomarker 57 echocardiographic parameters 56 PRECiSE 56 Group RTOG 56 PIX# [002] 56 REACH Registry 56 CIMZIA TM certolizumab pegol 56 Randomized trials 56 AVOREN 56 RE LY ® 56 Kaplan Meier analysis 55 univariate 55 MERLIN TIMI 55 genotype phenotype 55 TIMP 1 55 GAMMAGARD 55 Randomized Evaluation 55 multicentre prospective 55 retrospective observational study 55 retrospective cohort 55 Pharmacokinetic parameters 55 clinicopathologic 55 prospective multicenter study 55 pharmacokinetic PK 55 clinicopathological features 55 ANCOVA 55 Operative mortality 54 Multicenter Phase 54 REMINYL ® 54 adjuvant systemic 54 SYNTAX trial 54 Meta analyzes 54 CAMMS# 54 PARTNER Trial 54 secondary efficacy endpoint 54 LUX Lung 54 prospectively defined 54 National Oncologic PET 54 BRIM2 54 atherothrombotic disease 54 OvaRex MAb 54 RECIST Response Evaluation Criteria 54 ENDEAVOR clinical 54 HCV SPRINT 54 TAXUS VI 54 stepwise logistic regression 54 LUMINATE 54 REVIVE Diabetes 54 Echocardiographic 54 REALITY Trial 54 ICAEL 54 vidofludimus 54 NHANES III 54 multicenter multinational 54 FDG PET 54 endophenotypes 54 Clinical Antipsychotic Trials 54 randomized Phase 2b 54 SF #v# 54 EDEMA3 54 CHAMPION PCI 54 HER2 positive metastatic breast 53 prospective observational studies 53 prospectively stratified 53 PITX2 methylation 53 Endocrine Society #st 53 ICD Registry 53 Nord Trøndelag Health 53 KRAS variant 53 Oncotype DX Recurrence Score 53 trastuzumab emtansine T DM1 53 Edge STudy 53 Exelixis XL# 53 Intervention Trial GAIT 53 Coronary Artery Calcium 53 K ras mutations 53 ACCORD Eye 53 Tweet Sentiments web 53 SLNB 53 papillary renal cell carcinoma 53 serum leptin 53 clinicopathological 53 Glufosfamide 53 STRATEGY FOR AN OPEN 53 EchoCRT 53 #F FDG PET 53 DNA methylation markers 53 placebo controlled Phase III 53 CaPSURE 53 ONTARGET 53 nodal metastases 53 multivariate regression analysis 53 multivariate Cox 53 PRESEPT 53 Registry NOPR 53 SABCS 53 Renal Cell Carcinoma RCC 53 NCCTG N# 53 chromosome #p# [002] 53 TMC# C# 52 MEND CABG 52 exponential regression 52 SPIRIT FIRST 52 genomic biomarker 52 PCWP 52 evaluating REVLIMID 52 LEUKINE 52 Radiation Therapy Oncology 52 periprocedural MI 52 Patient Registry 52 hematological parameters 52 nonrandomized 52 multivariate analyzes 52 MEND CABG II 52 logistic regression analysis 52 multivariable logistic regression 52 Pharmacodynamic 52 NOPR 52 Ischemic 52 treatment naive genotype 52 desvenlafaxine succinate 52 randomized Phase III 52 Lung Injury 52 dose dose escalation 52 intra abdominal abscess 52 Intervention Effectiveness 52 blinded randomized placebo controlled 52 WEBENCH Visualizer 52 semistructured interviews 52 ACS NSQIP 52 Cardiopulmonary bypass 52 perioperative mortality 52 eTag assays 52 AMB IBI 52 relapsed MM 52 etiologic 52 TAXUS IV 52 OZURDEX 52 prognostic variables 52 SYMMETRY trial 52 CIMZIA TM 52 PROLARIS 52 LONG BEACH Sportfishing Berth 52 PLCO 52 unmeasured confounding 52 prospective multicenter 52 histologically confirmed 52 recurrent malignant glioma 52 Solid Tumors 52 Glucosamine Chondroitin Arthritis 52 symptomatic VTE 52 Sociodemographic 52 NCCTG 52 HER2 expression 52 prospective longitudinal 52 genetic loci 52 pharmacodynamic PD 52 CR nPR 52 EVEREST II 52 KRAS mutation 52 ischemic cardiomyopathy 52 ProviderPoint 52 postintervention 52 RE LY 52 Descriptive statistics 52 interobserver 52 Haplotype 52 Multivariate logistic regression 52 florbetaben 52 Stenting Trial 52 EndoTAGTM 1 52 atherogenic dyslipidemia 52 NAIC RBC 52 HSCT 52 HIV AIDS BC CfE 52 Carotid Revascularization Endarterectomy vs. 52 RE LY trial 51 locoregional 51 EUS FNA 51 CAPRIE 51 CATIE AD 51 logistic regression analyzes 51 HH CAHPS 51 PreCISe study 51 Wood Preservative Chemicals 51 Phase 1a clinical 51 familial aggregation 51 rs# [004] 51 Pharm Olam International 51 schizophrenia schizoaffective disorder 51 pharmacodynamic effects 51 F FDG PET 51 APEX AMI trial 51 differential gene expression 51 Group B CALGB 51 NAMCS 51 Mantel Haenszel 51 Lewy bodies DLB 51 FDG PET imaging 51 Phase Ib study 51 intraobserver 51 elevated LDH 51 neoadjuvant 51 IRX 2 51 observational cohort study 51 AVADO 51 Brief Psychiatric 51 DJ BTMU barometer 51 histopathologic 51 ToGA 51 angiographic outcomes 51 ARCALYST ® rilonacept 51 BEXXAR Therapeutic Regimen 51 EURIDIS 51 Ovarian PLCO Cancer 51 androgen suppression 51 ug dose 51 Prostate Cancer Outcomes 51 Prostate Lung Colorectal 51 BARI 2D 51 adenoma recurrence 51 placebo controlled clinical 51 MAGE A3 ASCI 51 multiple logistic regression 51 lymphadenectomy 51 APTIVUS ritonavir 51 histologies 51 Thrombolysis 51 II Nutrition Cohort 51 pegylated interferon alfa 2b 51 Investigator Initiated 51 IMPROVE HF 51 immunohistochemical 51 neoadjuvant treatment 51 Syllego system 51 limiting generalizability 51 subgroup analyzes 51 NHANES #-# 51 ACCORD Lipid 51 TAXUS ATLAS 51 corticosteroid dose 51 NCDB 51 APTIVUS r 51 unstable angina pectoris 51 Angiographic 51 NABE Outlook 51 enzastaurin 51 GPRD 51 Home Buyer Seller 51 Outcome Measures 51 prospective nonrandomized 51 genotypic 51 Phase 1b 51 Computed Tomographic 51 polyarticular 51 Phase Ib Clinical Trial 51 elective percutaneous coronary 51 KRAS status 51 DLTs 51 MADIT II 51 placebo controlled dose escalation 51 Thorough QT 51 PERSEUS 51 GIK infusion 51 Azedra 51 NMIBC 50 randomized multicenter 50 imetelstat 50 Patient Outcomes 50 BR.# 50 VADT 50 microRNA profiling 50 microbiologically evaluable 50 schizophrenia CIAS 50 Arch Intern Med 50 multivariable analysis 50 Anticalin ® 50 immunohistochemical analysis 50 FirstGateways 50 catheter angiography 50 histological subtype 50 VCORE 50 treatment naïve genotype 50 CHARISMA trial 50 EOquin TM 50 assessing T DM1 50 phase IIIb 50 ACRIN 50 Quality Indicators 50 Poisson regression 50 NSABP B 50 Digital Mammographic Imaging 50 definite stent thrombosis 50 FGDC 50 Phase III psoriasis 50 ACUITY trial 50 haematologic 50 Sequencing Systems 50 multicenter prospective 50 pharmacokinetic pharmacodynamic 50 Relevant Triad Guaranty 50 Dialysis Outcomes 50 PROactive study 50 Val HeFT 50 #-#-# Vyacheslav Kozlov 50 Subgroup analysis 50 meta regression 50 Swedish Mammography Cohort 50 baseline HbA1c 50 IgG1 antibody 50 MIVI TRUST 50 EMBLEM ™ 50 postoperative mortality 50 HeFT 50 mean ± SEM 50 placebo fluoxetine 50 Trial PCPT 50 ZACTIMA 50 stage IIIB 50 Complications Trial 50 CGDI 50 COPAXONE R 50 Lp PLA 2 50 Clinical Xchange 50 RTOG 50 retrospective cohort study 50 genomewide association study 50 NSTE ACS 50 dosing cohort 50 Virulizin R 50 virological response 50 gene polymorphisms 50 genotypic resistance 50 MGd 50 #p# [003] 50 adjuvant tamoxifen 50 skin sterol 50 CSF Assurance 50 SWOG 50 Secondary efficacy endpoints 50 death reinfarction 50 TNM staging 50 PSADT 50 Prostate Cancer Prevention 50 Bowel Project NSABP 50 sleeve lobectomy 50 histologically 50 rALLy trial 50 Ovarian Cancer Screening 50 DF HCC 50 elotuzumab 50 SSc 50 recurrent glioma 50 longitudinal cohort study 50 IP Multicast 50 substudy 50 MADIT CRT trial 50 baseline LDH 50 SNP rs# [002] 50 prospective cohort 50 allele frequencies 50 multicentre randomized 50 quantitative RT PCR 50 prospective observational cohort 50 estimated GFR 50 psychiatric comorbidities 50 COMT genotype 50 Osteoporotic Fractures 50 Screening Trial DMIST 50 XL# XL# XL# 50 Multicenter Automatic Defibrillator Implantation 50 PACCE trial 50 serum phosphorous 50 Primary endpoints 50 Renal dysfunction 50 eculizumab therapy 50 angina myocardial infarction 50 non valvular atrial 50 alvespimycin 50 Kaplan Meier estimates 50 galiximab 50 Neuroepidemiology 50 ATACAND 50 hemodynamically significant 50 ELACYT 50 DAS# CRP 50 EGFR HER2 50 tolerability pharmacokinetics 49 JAMA. 49 Telephone Omnibus 49 NLSY 49 multicentre 49 Multifactor 49 pharmacodynamic parameters 49 WhatsUp Gold NetFlow 49 relapsing remitting MS RRMS 49 thyrotropin levels 49 KRAS mutations 49 plain radiographs 49 ORAL Solo 49 GLOBOCAN 49 RenalGuard System TM 49 tumor histology 49 Brucejack Area 49 Multicenter 49 ascending dose 49 TACI Ig 49 Logistic regression 49 Coronary artery calcification 49 serum estradiol 49 phosphorylated tau 49 Arch Gen Psychiatry 49 Bezielle 49 IPAH 49 UVIDEM 49 body louse genome 49 prelicensure 49 CARE HF 49 NCT# ClinicalTrials.gov 49 ExTRACT TIMI 49 ECOG 49 Interagency Registry 49 Vertebral Fracture 49 Data Extraction 49 Initiative K DOQI 49 dbGaP 49 ABSORB trial 49 NSABP 49 Neuradiab 49 transvaginal sonography 49 haplotype map 49 Purisma Data Hub 49 ConclusionThis 49 logistic regressions 49 PhG alpha 1 49 thoracoscopic lobectomy 49 underwent surgical resection 49 prognostic indicators 49 NESARC 49 Alpha Tocopherol Beta Carotene 49 prospective randomized multicenter 49 dose escalation Phase 49 linear regression analyzes 49 OLYMPIA registry 49 Unicenter ASM 49 cytoreductive nephrectomy 49 Psychol Med 49 EGFR mutation status 49 PCI ExTRACT TIMI 49 OPT CHF 49 subclinical hypothyroidism 49 fasting serum 49 Acute Coronary Syndromes 49 DEcIDE 49 undetectable HBV DNA 49 PRIALT 49 observational cohort 49 interferon gamma 1b 49 Intervention Effectiveness CATIE 49 Asthma Intervention 49 genomewide 49 arterial thromboembolic events 49 serum lipid levels 49 multivariable Cox 49 mcg albinterferon alfa 2b 49 EDEMA3 trial 49 Anceta 49 Interagency Coordinating Committee 49 nomograms 49 renal tumors 49 chemoradiotherapy 49 Intervention Trial 49 microRNA expression 49 MatchMetrix 49 constipation predominant IBS 49 Wisconsin Sleep Cohort 49 liver transplant recipients 49 PROactive 49 Stroke REGARDS study 49 Tarceva TM 49 Heart Transplant Recipients 49 Billable headcount 49 PRECISE trial 49 concurrent chemoradiation 49 angiographically 49 SYNTAX 49 Acute Coronary Syndromes ACS 49 migalastat HCl 49 CLARITY TIMI 49 Towering scholar 49 microarray experiments 49 TASQ 49 APEX AMI 49 Nonalcoholic fatty liver 49 DCE MRI 49 noninvasive outpatient 49 subanalysis 49 euthymic patients 49 pharmacodynamic markers 49 EndoTAG TM -1 49 hip BMD 49 Fracture Intervention Trial 49 diffusion tensor 49 Per Share Quarter Ended 49 PDE# inhibitors 49 SIMPADICO 49 Plicera 49 Multiple Ascending Dose 49 Prehypertension 49 CTEPH 49 microarray datasets 49 Normative Aging Study 49 metastatic HRPC 49 Subgroup analyzes 49 multicenter Phase II 49 bivariate 49 Biobanks 49 dosing cohorts 49 neoadjuvant chemotherapy 49 methotrexate therapy 49 Crohn Disease Activity 49 PRIMO CABG2 49 Halozyme Ultrafast Insulin 49 Multivariate analysis 48 subtrochanteric 48 oncologic outcomes 48 completely resected 48 inferential statistics 48 chromosome #q# [002] 48 PharmaPros 48 multicenter randomized controlled 48 lorcaserin Phase 48 randomized blinded 48 ABCSG 48 HispanTelligence ® 48 LibiGel Phase III 48 multivendor multitechnology Nokia NetAct 48 YONDELIS 48 lymphoblastoid cell lines 48 lipid lowering agents 48 MDRD 48 Kahalalide F 48 LV dysfunction 48 AGILECT R 48 null responder HCV 48 multicentric 48 clinical pharmacology studies 48 dose escalation 48 covariate 48 NATRECOR R 48 efficacy endpoint 48 NATRECOR ® 48 Sorafenib HCC Assessment 48 EORTC 48 TOLAMBA 48 NCIC CTG 48 Health Initiative Observational 48 ZEVALIN therapeutic regimen 48 genetic polymorphisms 48 Spartan EVTeam operating 48 TAXUS V 48 cobas HPV Test 48 CDKN2A 48 CSF biomarkers 48 DECIPHER 48 preclinical efficacy 48 Trial NLST 48 conditional logistic regression 48 venous thromboembolic disease 48 PubMatic AdPrice Index 48 Accelovance 48 RNA seq 48 mg/m2 cohort 48 MelaFind pivotal 48 Nation Spending Habits 48 transcriptional profiles 48 Zevalin consolidation 48 prostate cancer CaP 48 myeloproliferative 48 heeled Maadi neighborhood 48 retrospectively analyzed 48 seropositivity 48 coronary artery vasospasm 48 BioNumerik 48 evaluable patients 48 Phase IIa trials 48 SerDes transceivers 48 Population Demographics 48 Methods Retrospective 48 chemoprevention trials 48 Genedata Expressionist 48 viral kinetic 48 rs# rs# 48 prospective observational 48 voiceband 48 ABCB1 48 Interview Survey CHIS 48 colorectal adenoma 48 Nutrition Examination 48 Cancer Genetic Markers 48 multivariable adjusted 48 Kidney Disease Outcomes 48 Framingham Offspring 48 recurrent glioblastoma multiforme 48 TRITON TIMI 48 Heart Failure Trial 48 ARB telmisartan 48 Secondary endpoints 48 ActiPix 48 ARDIS 48 Critical Elements 48 spirometric 48 biochemical recurrence 48 Survey Methodology 48 atherosclerotic renal artery stenosis 48 Women Ischemia Syndrome 48 farletuzumab 48 TCF#L# 48 TrendTrader system 48 agalsidase alfa 48 miRview ™ squamous 48 SUVmax 48 radical nephrectomy 48 CLARITY study 48 NIHSS score 48 rxRNA 48 5 HT2C receptor 48 QOPI 48 y h r 48 BIBW 48 nab paclitaxel 48 coinfected patients 48 Initiate Systems Inc 48 HYVET 48 Platinol ® cisplatin 48 NELS 48 cisplatin vinorelbine 48 randomized controlled trials RCTs 48 DAS# remission 48 Scopus Custom 48 IL#B 48 PRoFESS 48 PROPERTY TRANSFERS 48 myocardial viability 48 multicenter randomized Phase 48 InvestorsKeyhole various news 48 DEFER 48 Baltimore Longitudinal Study 48 COSIRA trial 48 childhood acute lymphoblastic 48 Next Generation Sequencing NGS 48 SEER registry 48 variant rs# 48 PETNET Solutions 48 PROPEL trial 48 PACIFIC NORTHWEST 48 clinically localized prostate 48 links summarizes personalizes 48 Spherion Employment Report 48 Observational Study 48 EuroSCORE 48 Main Outcome Measure 48 lenalidomide dexamethasone 48 FOSRENOL ® 48 endoscopic remission 48 viral kinetics 48 HIV coinfected 48 ADAGIO study 48 risk reducing salpingo 48 STEP BD 48 transcriptional profiling 48 CorVue ™ 48 HPA Consultants 48 lumbar spine BMD 48 longitudinal observational study 48 conventional coronary angiography 48 multicenter clinical trials 48 spokesman Naoya Narita 48 Hepatotoxicity 48 pCR 48 ISPO institute 48 advanced adenoma 48 Non Alcoholic Steatohepatitis 48 nonnegligent manslaughter forcible rape 48 antithrombotic therapy 48 AMORTIZATION OF INTANGIBLE ASSETS 48 nondiabetic patients 48 HOMA IR 48 psychiatric comorbidity 48 cerebral oximetry 48 multicenter trials 48 percutaneous vertebroplasty 48 Cardio3KG 48 Kaplan Meier method 48 chromosome #p#.# 48 APOE genotype 48 mg/m2 dose 48 Chevrolet SILVERADO 48 liver histology 48 Prospective Multicenter 48 retailing vending 48 neuropathologic 48 IVIVC 48 logistic regression model 48 Versant Object Database 47 olanzapine LAI 47 #S rRNA 47 Termed Massively Parallel 47 dyslipidaemia 47 intestinal permeability 47 coronary revascularization 47 Contrast Echocardiography 47 MLH1 47 plasma pharmacokinetics 47 MADIT CRT 47 variance ANOVA 47 information visit www.chadbourne.com 47 NICE SUGAR 47 neratinib 47 subcutaneous PRO 47 digit dial RDD 47 PRX# 47 left ventricular systolic 47 susceptibility loci 47 prospective randomized placebo 47 n4a 47 HGPIN 47 Affymetrix microarray technology 47 randomized Phase IIb 47 mapping trenching 47 APPRAISE 47 Ocular Hypertension Treatment 47 KIF6 carriers 47 generalized estimating 47 PROTECT II 47 indels 47 TURBT 47 ATTAIN 47 AVERROES 47 ICD therapy 47 Phenotype 47 postoperative chemotherapy 47 xCELLigence System 47 J Immunol 47 ER CHOP 47 refractory colorectal cancer 47 VNTR 47 Diabetes Complications 47 http:/events.fai.org 47 logistic regression models 47 EGFR TKIs 47 randomizing patients 47 controlled multicenter 47 BCR ABL1 47 antiarrhythmic drug 47 PON1 activity 47 multivariate logistic regression 47 parathyroidectomy 47 acute coronary syndromes ACS 47 mixed hyperlipidemia 47 Ceplene/IL-2 47 PreDx DRS 47 prespecified 47 hepatic resection 47 QSM Associates software 47 Dietary Modification Trial 47 Bipolar Disorder STEP BD 47 comorbid depression 47 Trofex 47 efficacy evaluable 47 DATATRAK eClinical ™ 47 OPCAB 47 PROPEL 47 By KRIS RUSSELL 47 preserved ejection fraction 47 Enzyme Replacement Therapy 47 nonmetastatic 47 heavily pretreated 47 GHIS 47 AGY Asia 47 aortic insufficiency 47 recurrent GBM 47 phylogenetic analyzes 47 Androxal TM 47 placebo controlled Phase 47 NSQIP 47 Frasergold Project 47 ASSERT 47 biomolecular interactions 47 iPrEx study 47 Rigorous scientific 47 mutated K ras 47 bivariate analysis 47 taxane therapy 47 ENGAGE AF TIMI 47 Innovation OCRI 47 carotid revascularization 47 multicenter randomized 47 SCr 47 Multiple logistic regression 47 vivo preclinical studies 47 underwent resection 47 everolimus eluting stent 47 COU AA 47 SUA Insurance 47 radiographic outcomes 47 HuMax 47 MYH9 gene 47 Vectibix monotherapy 47 TIS eFLOW 47 MPFS 47 CARAVAN R 47 patients undergoing CABG 47 nCounter Analysis System 47 HIV HCV coinfected 47 Nationwide Inpatient Sample 47 Univariate 47 UPLYSO 47 folate supplementation 47 thyroid carcinoma 47 pretest probability 47 catechol O methyltransferase 47 transcriptome sequencing 47 Biomerk Tumorgrafts 47 Attributed equity 47 VELCADE melphalan 47 premorbid 47 Therapeutic Arthritis 47 Liraglutide Effect 47 Division IA Conferences 47 carotid plaque 47 CC genotype 47 CDISC ODM 47 androgen deprivation 47 flurpiridaz F 47 CMHCs 47 Claire Danes Ted Danson 47 Hp2 2 47 resectable pancreatic cancer 47 Multiethnic Cohort 47 metachronous 47 multicenter Phase 47 Supplementary Table 47 Comorbidity 47 familial AF 47 evaluable subjects 47 CIMZIA R 47 sirolimus eluting stents 47 Talotrexin 47 Endovascular System 47 chest radiographs 47 multivessel disease 47 Framingham Offspring Study 47 virologic 47 AIM HIGH 47 APTIMA HPV 47 Gene Ontology 47 PD LID 47 Study ARIC 47 VKORC1 47 ArcSight SIEM Platform 47 CRQ 47 Nonoperating expense 47 Illumina Infinium 47 ICD implantation 47 Multi Ethnic Study 47 Goldpines 47 PECARN 47 peptidome 47 Governmental statistics 47 postoperative radiotherapy 47 NovoSeven ® 47 Hypertriglyceridemia 47 carotid endarterectomy CEA 47 BSIs 47 Investment Svcs 47 electrophysiologic 47 BRCA2 mutation carriers 47 potent suppressor 47 element geochemical 47 GSK# [001] 47 HCV RESPOND 2 46 SPIVA methodology 46 RRMS patients 46 VITAL Trial 46 #-#-# Fredrik Modin 46 afatinib 46 QTinno TM 46 BRAF V#E mutation 46 Replication NCS R 46 JVRS 46 del 5q MDS 46 Sequenced Treatment Alternatives 46 Septic Shock 46 HMG CoA reductase inhibitors 46 Chandra Observatory 46 Randomized controlled 46 CT perfusion 46 inVentiv Clinical 46 Cancer Incidence 46 IMP# 46 Velcade bortezomib 46 CURE AF 46 KN excels 46 dose escalation phase 46 Geospatial Data 46 chromosome #q#.# [001] 46 prospectively randomized 46 multiplex PCR 46 certolizumab pegol 46 Destum Partners 46 Urocidin TM 46 Acetonide 46 Princeton Softech Optim 46 randomized discontinuation 46 placebo controlled trials 46 HELM Analytics 46 tissue microarrays 46 Dynamic Logic MarketNorms 46 prospective multicenter randomized 46 perinatal outcomes 46 Parallel Engines 46 PHX# 46 NIH CPSI 46 randomized multicenter trial 46 CORE OM 46 periprocedural 46 Phase #/#a 46 Radius Studio 46 radical cystectomy 46 Mammographic 46 Corporation NASDAQ INFA 46 #S rRNA gene 46 amnestic mild cognitive impairment 46 Beta catenin pathway 46 AMERIGROUP Corporation 46 USAISR 46 liposomal formulation 46 NHAMCS 46 NHANES 46 pharmacodynamics PD 46 Ellen Lewandowski 46 echocardiographic 46 underwent CABG 46 hemodialysis patients 46 GRAVITAS trial 46 CUSTOM III 46 glufosfamide 46 authors hypothesized 46 GnRH agonist 46 patientswith 46 AZOR 46 TransUnion Trend 46 Genz # 46 OUTLOOK Highlights 46 IntegriGuard 46 Educational Longitudinal Study 46 prostate carcinoma 46 sociodemographic characteristics 46 Eurozone EA# 46 REFORMERS UNANIMOUS Weekly 46 Bango Analytics 46 randomized multicenter Phase III 46 serum selenium 46 univariate analysis 46 HAM D# scores 46 Tasigna prolongs 46 periodically reassessed 46 NOX E# 46 Memory Study WHIMS 46 bendamustine 46 multicenter randomized clinical 46 gene expression profiles 46 International HapMap Project 46 AI AN 46 Y.# 46 EMPHASIS HF trial 46 serum vitamin D 46 samalizumab 46 JDrew Atlanta 46 racemic baclofen 46 oral anticoagulation 46 Bucuvalas Inc. 46 Anas Younes MD 46 gene rearrangements 46 STRATEC Group 46 pharmacodynamics 46 neuroregenerative